Who are CC-5013 plus dexamethasone's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Thalidomide plus dexamethasone.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/cc-5013-plus-dexamethasone.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

CC-5013 plus dexamethasone — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

CC-5013 plus dexamethasone (CC-5013 plus dexamethasone) competitive landscape: 1 comparator, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Immunomodulatory agent plus corticosteroid. Area: Oncology.

phase 3 Immunomodulatory agent plus corticosteroid Cereblon (CRBN); glucocorticoid receptor Oncology Small molecule Live · refreshed every 30 min

Target snapshot

CC-5013 plus dexamethasone (CC-5013 plus dexamethasone) — Celgene. CC-5013 (lenalidomide) is an immunomodulatory agent that enhances T-cell proliferation and cytokine production while dexamethasone provides corticosteroid-mediated anti-inflammatory and anti-proliferative effects.

Comparator set (1 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
CC-5013 plus dexamethasone TARGET	CC-5013 plus dexamethasone	Celgene	phase 3	Immunomodulatory agent plus corticosteroid	Cereblon (CRBN); glucocorticoid receptor
Thalidomide plus dexamethasone	Thalidomide plus dexamethasone	Grupo de Estudos Multicentricos em Onco-Hematologia	phase 3	Immunomodulatory agent plus corticosteroid	Cereblon (CRBN), glucocorticoid receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Immunomodulatory agent plus corticosteroid class)

Celgene · 1 drug in this class
Grupo de Estudos Multicentricos em Onco-Hematologia · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). CC-5013 plus dexamethasone — Competitive Intelligence Brief. https://druglandscape.com/ci/cc-5013-plus-dexamethasone. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing